- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04334356
Testing of a Mobile Web App to Decrease Posttraumatic Stress Symptoms in Women After Sexual Assault
February 20, 2023 updated by: University of North Carolina, Chapel Hill
Pilot Testing of a Mobile Web App to Mitigate Posttraumatic Stress Symptoms (PTSS) After Sexual Assault
Interventions are available to all adult women sexual assault survivors to reduce the risk of pregnancy and sexually transmitted infection, yet no interventions are provided to reduce posttraumatic stress.
This pilot study tests the ability of a smartphone-based web app to prevent and reduce posttraumatic stress in women sexual assault survivors.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80909
- UCHealth Memorial Central Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina at Chapel Hill, SANE Program
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 99 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Present for emergency care within 72 hours of sexual assault
- Receive a sexual assault nurse examiner (SANE) exam
- Alert and oriented
Exclusion Criteria:
- Unable to consent due to intoxication, serious injury preventing ability to hear, speak, or see to consent, or other causes
- Prisoners
- Pregnant women
- Women living with assailant who plan to continue living with assailant
- Women with fractures from the assault
- Admitted patients
- Women who do not have a smartphone with continuous service for the past 12 months
- Inability to read and speak English
- No mailing address
- SANE exam took place >72 hours ago
- Patient previously enrolled in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: App Intervention
All participants will receive the web app for prevention of posttraumatic stress.
|
App for preventing development of posttraumatic stress based on cognitive behavioral techniques.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Week 6 to Month 6 in PCL-5 Scores
Time Frame: change from six weeks and six months
|
The Posttraumatic Stress Disorder (PTSD) Checklist (PCL-5) for Diagnostic and Statistical Manual-5 (DSM-5) is the gold standard measure of PTSD symptom severity.
Range: 0-80.
Higher scores indicate worse outcomes.
The investigators will assess whether reductions in PTSD symptoms from six weeks to six months are associated with reductions in anxiety sensitivity from the initial visit to six months.
Change trajectories and mean scores of PCL-5 scores will be assessed over the 6 months of study follow-up.
These patterns will be compared to prior observational research conducted in the lab.
|
change from six weeks and six months
|
|
Change from Week 6 to Month 6 in PROMIS Anxiety Scores
Time Frame: change from six weeks, and six months
|
The Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety measures self-reported fear (fearfulness, panic), anxious misery (worry, dread), hyperarousal (tension, nervousness, restlessness), and somatic symptoms (racing heart, dizziness) over the past seven days.
Each question has five response options ranging in value from one to five (1=never; 2=rarely; 3=sometimes; 4=often; 5=always).
To find the total raw score, sum the values of the response to each question.
The lowest raw score is 8; the highest raw score is 40.
A higher score represents more of the concept being measured.
The investigators will assess whether reductions in PROMIS symptoms from six weeks to six months are associated with reductions in anxiety sensitivity from the initial visit to six months.
Change trajectories and mean scores of PROMIS scores will be assessed over the 6 months of study follow-up.
These patterns will be compared to prior observational research conducted in the lab.
|
change from six weeks, and six months
|
|
Change from Baseline to Week 6 in ASI Scores
Time Frame: change from Initial to six weeks
|
Anxiety Sensitivity Index-3 (ASI) is a 16-item self-report questionnaire that assesses fear of anxiety sensations.
Each item is scored on a 5-point Likert scale (0 to 4) with total score ranging from a minimum of 0 to a maximum of 64 (higher scores indicate greater fear of anxiety sensations).
The investigators will assess patterns of ASI scores over the 6 months of study follow-up, specifically using t-tests to test for change from intake to six weeks and six months.
|
change from Initial to six weeks
|
|
Change from Week 6 to Month 6 in PROMIS Depression Scores
Time Frame: change from six weeks, and six months
|
The PROMIS Depression assesses self-reported negative mood (sadness, guilt), views of self (self-criticism), and social cognition (loneliness), as well as decreased positive affect and engagement (loss of interest, meaning, and purpose) over the past seven days.
Each question has five response options ranging in value from one to five (1=never; 2=rarely; 3=sometimes; 4=often; 5=always).
To find the total score, sum the values of the response to each question.
The lowest raw score is 8; the highest is 40.
A higher score represents more of the concept being measured.
The investigators will assess whether reductions in PROMIS symptoms from six weeks to six months are associated with reductions in anxiety sensitivity from the initial visit to six months.
Change trajectories and mean scores of PROMIS scores will be assessed over the 6 months of study follow-up.
These patterns will be compared to prior observational research conducted in the lab.
|
change from six weeks, and six months
|
|
Change from Week 6 to Month 6 in Pain Related to Assault
Time Frame: change from six weeks, and six months
|
Pain Severity Numeric Rating Scale and Regional Pain Scale.
The pain numeric rating scale (Pain NRS) consists of an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate worse pain.
Participants chose the number that best described the pain during the last week.
The investigators will assess whether reductions in pain NRS from six weeks to six months are associated with reductions in anxiety sensitivity from the initial visit to six months.
Change trajectories and mean scores of pain NRS scores will be assessed over the 6 months of study follow-up.
These patterns will be compared to prior observational research conducted in the lab.
|
change from six weeks, and six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Insomnia Severity Index Scores
Time Frame: one week, six weeks, six months
|
The Insomnia Severity Index (ISI) is a 7-item self-report questionnaire that provides a measure of insomnia severity based on several indicators (e.g., difficulty falling asleep, satisfaction with sleep, degree of impairment with daytime functioning).
It has adequate internal consistency and temporal stability, has been validated against sleep diary and polysomnography data and was sensitive to change in several insomnia treatment studies.
The ISI scale range is: minimum = 0, maximum = 28.
Lower is considered 'better sleep', while higher is considered 'worse sleep/more insomnia'.
This will be assessed at one week, six weeks, and six months to determine whether reductions in ISI from six weeks to six months are associated with reductions in anxiety sensitivity from the initial visit to six months.
Change trajectories and mean scores of ISI scores will be assessed over the 6 months of study follow-up.
These patterns will be compared to prior observational research conducted in the lab.
|
one week, six weeks, six months
|
|
Somatic Symptoms
Time Frame: one week, six weeks, six months
|
A previously used questionnaire from the investigator's lab will be used to measure somatic symptoms.
This measure is a 21-item self-report measure assessing various somatic symptoms (e.g., headaches, fatigue, feeling faint, stomach distress).
Items are rated on a 0-10 point scale, with total scores ranging from 0 to 210.
Higher scores indicate worse symptoms.
This will be assessed at one week, six weeks, and six months.
The investigators will assess whether reductions in somatic symptoms from six weeks to six months are associated with reductions in anxiety sensitivity from the initial visit to six months.
Change trajectories and mean scores of somatic symptoms scores will be assessed over the 6 months of study follow-up.
These patterns will be compared to prior observational research conducted in the lab.
|
one week, six weeks, six months
|
|
Association between Change in General Health and Anxiety Sensitivity
Time Frame: one week, six weeks, six months
|
PROMIS Global Health-Physical Health Component.
The PROMIS was developed by the National Institutes of Health and uses domain-specific measures to assess patient well-being.
It uses a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.
Higher scores represent poorer health status.
This will be assessed at one week, six weeks, and six months.
The investigators will assess whether reductions in PROMIS symptoms from six weeks to six months are associated with reductions in anxiety sensitivity from the initial visit to six months.
Change trajectories and mean scores of PROMIS scores will be assessed over the 6 months of study follow-up.
These patterns will be compared to prior observational research conducted in the lab.
|
one week, six weeks, six months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Nicole Short, PhD, University of Nevada, Las Vegas
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 30, 2020
Primary Completion (Actual)
November 18, 2022
Study Completion (Actual)
November 18, 2022
Study Registration Dates
First Submitted
April 1, 2020
First Submitted That Met QC Criteria
April 1, 2020
First Posted (Actual)
April 6, 2020
Study Record Updates
Last Update Posted (Estimate)
February 21, 2023
Last Update Submitted That Met QC Criteria
February 20, 2023
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-3399
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Deidentified individual data that supports the results will be shared by reasonable request beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.
IPD Sharing Time Frame
Data will become available 9 to 36 months following publication and will remain available for five years.
IPD Sharing Access Criteria
The investigator who proposes to use the data has IRB, IEC, or REB approval, as applicable, and an executed data use/sharing agreement with UNC.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Posttraumatic Stress Disorder
-
Sofie FolkeAarhus University Hospital; Copenhagen Trial Unit, Center for Clinical Intervention... and other collaboratorsNot yet recruiting
-
University Hospital, ToursCompletedPostTraumatic Stress DisorderFrance
-
ARQ National Psychotrauma CentreLeiden University Medical CenterEnrolling by invitationPosttraumatic Stress Disorder (PTSD)Netherlands
-
The University of Texas Health Science Center at...University of Pennsylvania; Brooke Army Medical Center; C.R.Darnall Army Medical... and other collaboratorsCompletedPosttraumatic Stress Disorder (PTSD)United States
-
Icahn School of Medicine at Mount SinaiCompletedPosttraumatic Stress Disorder (PTSD)United States
-
Berlin Center for the Treatment of Torture VictimsCompletedPosttraumatic Stress Disorder (PTSD)Germany
-
TEMPVA Research Group, Inc.C.R.Darnall Army Medical Center; VA Boston Healthcare System; Central Texas Veterans...UnknownPosttraumatic Stress Disorder, Combat-relatedUnited States
-
VA Office of Research and DevelopmentCompletedPosttraumatic Stress Disorder (PTSD)United States
-
Michael E. DeBakey VA Medical CenterSouth Central VA Mental Illness Research, Education & Clinical CenterCompletedPosttraumatic Stress Disorder (PTSD)United States
-
VA Office of Research and DevelopmentCompleted
Clinical Trials on Mobile Web App
-
Oregon Center for Applied Science, Inc.National Heart, Lung, and Blood Institute (NHLBI)CompletedBlood Pressure | WeightUnited States
-
SEPAR- EPOCRecruiting
-
University of South DakotaNot yet recruitingCervical Cancer ScreeningUnited States
-
The Ottawa HospitalCompletedMobile Apps | Immunization | Adverse Event Following ImmunisationCanada
-
Oregon Research InstituteCompleted
-
University of OregonNational Institute on Drug Abuse (NIDA)CompletedDepression | Anxiety | Substance Use | Conduct Disorders in AdolescenceUnited States
-
University of Wisconsin, MadisonCompleted
-
Pamela HullUnited States Department of Agriculture (USDA)RecruitingObesity, Childhood | Physical Inactivity | Nutrition, Healthy | Sleep, InadequateUnited States
-
The University of Hong KongNorth District Hospital; Queen Mary Hospital, Hong Kong; Pamela Youde Nethersole... and other collaboratorsUnknownSelf Inflicted Injury | Suicide and Self Inflicted InjuryHong Kong
-
University of ValenciaMinistry of Science and InnovationCompleted